Re‐infection · children with lower urinary tract infection
It is very uncertain whether single‐dose changes re‐infection compared with short‐course (3‐7 days) antibiotics (very low certainty).
1 finding from 1 review
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether single‐dose changes persistent bacteriuria compared with conventional 10‐day antibiotic treatment (very low certainty).
1 finding from 1 review
Persistent symptoms · children with lower urinary tract infection
It is very uncertain whether single‐dose changes persistent symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
1 finding from 1 review
Persistent bacteriuria and symptoms · children with lower urinary tract infection
It is very uncertain whether single‐dose changes persistent bacteriuria and symptoms compared with conventional 10‐day antibiotic treatment (very low certainty).
1 finding from 1 review
Recurrence · children with lower urinary tract infection
It is very uncertain whether single‐dose changes recurrence compared with conventional 10‐day antibiotic treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether the intervention changes persistent bacteriuria (very low certainty).
1 finding from 1 review
Intervention not reported
Recurrence · children with lower urinary tract infection
It is very uncertain whether the intervention changes recurrence (very low certainty).
1 finding from 1 review
Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in clinical vertebral fractures compared with placebo (low certainty).
1 finding from 1 review
RR 3.03 [0.32, 28.44]
Studies not reported
Low
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.56 [0.2, 1.61]
Studies not reported
Moderate
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Wrist fractures · postmenopausal women at lower risk of fractures1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 1.41 [0.81, 2.47]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
1 finding from 1 review
IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a hyper‐response to stimulation based on at least one ORT measure
Anticipated high responders: higher showed no clear difference in IU vs 100 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
300/450 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 300/450 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
400/450 IU vs 300 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 400/450 IU vs 300 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 450 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in IU vs 450 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in IU vs 100 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
225/200 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in 225/200 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review